836-21-5

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-3,5-dimethylpiperidin-4-one is used as a key intermediate in the synthesis of various drugs for its ability to contribute to the development of new pharmaceutical compounds with potential therapeutic benefits.
Used in Agrochemical Industry:
1-Benzyl-3,5-dimethylpiperidin-4-one is used in the development of agrochemicals, where its unique molecular structure can be leveraged to create effective products for agricultural applications, such as pesticides or herbicides, to enhance crop protection and yield.
Used in Organic Synthesis:
BDMP is utilized as a building block in organic synthesis, allowing chemists to create a variety of complex organic compounds for research and commercial purposes, further expanding its applications across different industries.

Upstream product

• 91600-22-5 1-benzyl-3-methyl-4-oxopiperidine N,N-dimethylhydrazone 
• 74-88-4 methyl iodide 
• 34737-89-8 1-Benzyl-3-methyl-4-piperidon 
• 42324-07-2 2,4-dimethyl-3-oxo-pentanedioic acid diethyl ester 
• 110331-19-6 1-benzyl-3,5-dimethyl-4-oxo-piperidine-3,5-dicarboxylic acid diethyl ester 

Downstream Products

• 723308-54-1 1-benzyl-3,5-dimethylpiperidin-4-amine 
• 91599-86-9 1-benzyl-4-hydroxy-3,5-dimethylpiperidine 
• 31206-92-5 4-benzyl-3,5-dimethyl-pyridine 
• 20579-43-5 3,4,5-trimethylpyridine 
• 473838-87-8 1-Carbethoxy-3,5-dimethyl-4-piperidone 
• 473838-86-7 4-amino-1-carbethoxy-3,5-dimethylpiperidine 
• 102372-29-2 1,4-dibenzyl-3,5-dimethyl-piperidin-4-ol 
• 101449-46-1 4-ethyl-1-benzyl-3,5-dimethyl-piperidin-4-ol 
• 102471-57-8 1-benzyl-3,4,5-trimethyl-piperidin-4-ol 
• 101778-33-0 1-benzyl-4-butyl-3,5-dimethyl-piperidin-4-ol 

Relevant academic research and scientific papers

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

Chemokine receptor antagonists and methods of use thereof

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

CCR8 INHIBITORS

Disclosed is an inhibitor of CCR8 that is represented by Structural Formula (I). Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a CCR8 inhibitor represented by Structural Formula (I). Also disclosed is a method of treating inflammatory disorders in a subject by administering a CCR8 inhibitor to the subject.

CCR8 INHIBITORS

Disclosed are CCR8 inhibitors represented by Structural Formulas (I). The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

Chemokine receptor anagonists and methods of use therefor

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

1-benzyl-3,5-dimethyl-4-piperdyl ester of a Hantzsch dihydropyridine

The compound of the formula STR1 is disclosed to have a less rapid decrease in blood pressure in its use as an antihypertensive.